RSS-Feed abonnieren
DOI: 10.1055/s-0044-1779282
Predictive Value of Corrected 18F-FDG PET/CT Baseline Parameters for Primary DLBCL Prognosis: A Single-center Study
Abstract
Objective The purpose of this study was to evaluate the prognostic significance of corrected baseline metabolic parameters in fluorodeoxyglucose positron emission tomography imaging (18F-FDG PET/CT) for 3-year progression-free survival (PFS) in patients with primary diffuse large B cell lymphoma (DLBCL).
Patients and Methods Retrospective clinical and pathological data were collected for 199 patients of DLBCL diagnosed between January 2018 and January 2021. All patients underwent 18F-FDG PET/CT scans without any form of treatment. The corrected maximum standardized uptake value (corSUVmax), corrected mean standardized uptake value (corSUVmean), corrected whole-body tumor metabolic volume sum (corMTVsum), and corrected total lesion glycolysis of whole body (corTLGtotal) were corrected using the SUVmean in a 1-cm diameter mediastinal blood pool (MBP) from the descending thoracic aorta of patients. Kaplan–Meier survival curves and Cox regression were used to examine the predictive significance of corrected baseline metabolic parameters on 3-year PFS of patients. The incremental values of corrected baseline metabolic parameters were evaluated by using Harrell's C-indices, receiver operating characteristic, and Decision Curve Analysis.
Results The multivariate analysis revealed that only the National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and corMTVsum had an effect on 3-year PFS of patients (p < 0.05, respectively). The Kaplan–Meier survival analysis demonstrated significant differences in PFS between the risk groups classified by corSUVsum, corMTVsum, and corTLGtotal (log-rank test, p < 0.05). The predictive model composed of corMTVsum and corTLGtotal surpasses the predictive performance of the model incorporating MTVsum and TLGtotal. The optimal performance was observed when corMTVsum was combined with NCCN-IPI, resulting in a Harrell's C index of 0.785 and area under the curve values of 0.863, 0.891, and 0.947 for the 1-, 2-, and 3-year PFS rates, respectively.
Conclusion The corMTVsum offers significant prognostic value for patients with DLBCL. Furthermore, the combination of corMTVsum with the NCCN-IPI can provide an accurate prediction of the prognosis.
* These authors contributed equally to this work and retain the first authorship.
Publikationsverlauf
Artikel online veröffentlicht:
13. Februar 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010; 60 (06) 393-408
- 2 Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology (Am Soc Hematol Educ Program) 2011; 498-505
- 3 Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015; 125 (01) 22-32
- 4 International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 (14) 987-994
- 5 Ziepert M, Hasenclever D, Kuhnt E. et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. [published correction appears in J Clin Oncol 2011 Feb 20;29(6):779] J Clin Oncol 2010; 28 (14) 2373-2380
- 6 Zhou Z, Sehn LH, Rademaker AW. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123 (06) 837-842
- 7 Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 2014; 14 (06) 460-467.e2
- 8 Horn H, Ziepert M, Becher C. et al; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121 (12) 2253-2263
- 9 Cheson BD, Pfistner B, Juweid ME. et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (05) 579-586
- 10 Juweid ME, Stroobants S, Hoekstra OS. et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25 (05) 571-578
- 11 Cheson BD, Fisher RI, Barrington SF. et al; Alliance, Australasian Leukaemia and Lymphoma Group, ; Eastern Cooperative Oncology Group, ; European Mantle Cell Lymphoma Consortium, ; Italian Lymphoma Foundation, ; European Organisation for Research, ; Treatment of Cancer/Dutch Hemato-Oncology Group, ; Grupo Español de Médula Ósea, ; German High-Grade Lymphoma Study Group, ; German Hodgkin's Study Group, ; Japanese Lymphorra Study Group, ; Lymphoma Study Association, ; NCIC Clinical Trials Group, ; Nordic Lymphoma Study Group, ; Southwest Oncology Group, ; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27) 3059-3068
- 12 Gupta N, Singh N. To determine the prognostic significance of 18-fluorodeoxyglucose positron emission tomography/computed tomography scan-derived parameters (total lesion glycolysis and metabolic tumor volume) in patients of diffuse large B-cell lymphoma with only nodal involvement. Indian J Nucl Med 2020; 35 (02) 100-104
- 13 Guzmán Ortiz S, Mucientes Rasilla J, Vargas Núñez JA, Royuela A, Navarro Matilla B, Mitjavila Casanovas M. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with 18F-FDG PET/CT, in patients with diffuse large cell B-cell lymphoma. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020; 39 (06) 340-346
- 14 Ceriani L, Martelli M, Zinzani PL. et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 2015; 126 (08) 950-956
- 15 Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget 2016; 7 (50) 83544-83553
- 16 Meignan M, Cottereau AS, Versari A. et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 2016; 34 (30) 3618-3626
- 17 Shagera QA, Cheon GJ, Koh Y. et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging 2019; 46 (07) 1417-1427
- 18 Sasanelli M, Meignan M, Haioun C. et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 2014; 41 (11) 2017-2022
- 19 Gallicchio R, Mansueto G, Simeon V. et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol 2014; 92 (05) 382-389
- 20 Meignan M, Itti E, Bardet S. et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009; 27 (16) 2739-2741
- 21 Chiaravalloti A, Danieli R, Abbatiello P. et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2014; 41 (06) 1123-1132
- 22 Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 2017; 44 (suppl 1): 97-110
- 23 Cysouw MCF, Kramer GM, Hoekstra OS. et al. Accuracy and precision of partial-volume correction in oncological PET/CT studies. J Nucl Med 2016; 57 (10) 1642-1649
- 24 Hoetjes NJ, van Velden FH, Hoekstra OS. et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging 2010; 37 (09) 1679-1687
- 25 Taghvaei R, Zadeh MZ, Sirous R. et al. Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy. Am J Nucl Med Mol Imaging 2018; 8 (06) 407-414
- 26 Škor O, Bicanová L, Wolfesberger B. et al. Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma. Vet Comp Oncol 2021; 19 (01) 201-208
- 27 Adams HJ, de Klerk JM, Fijnheer R. et al. Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2015; 15 (11) 671-679
- 28 Wu S, Zhou Y, Hua HY. et al. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer 2018; 18 (01) 997
- 29 Kim DJ, Kim T, Jeong JY. et al. Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. Int J Hematol 2020; 111 (04) 559-566